The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
Open accessAbstract
Purpose: Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. Patients and Methods: In the absence of a prospective clinical trial in Europe, we conducted a retrospective study in centers that tested for ROS1 rearrangement. Eligible patients had stage IV lung adenocarcinoma, had ROS1 rearrangement according to fluorescent in situ hybridization, and had received crizotinib therapy through an individual off-label use. Best response was assessed locally using RECIST (version 1.1). All other data were analyzed centrally. Results: We identified 32 eligible patients. One patient was excluded because next-generation sequencing was negative for ROS1 fusion. Median age was 50.5 years, 64.5% of patients were women, and 67.7% were never-smokers. Thirty patients were evaluable for progression-free survival (PFS), and 29 patients were evaluable for best response. We observed four patients with disease progression, two patients with stable disease, and objective response in 24 patients, including five complete responses (overall response rate, 80%; disease control rate, 86.7%). Median PFS was 9.1 months, and the PFS rate at 12 months was 44%. No unexpected adverse effects were observed. Twenty-six patients received pemetrexed (either alone or in combination with platinum and either before or after crizotinib) and had a response rate of 57.7% and a median PFS of 7.2 months. Conclusion: Crizotinib was highly active at treating lung cancer in patients with a ROS1 rearrangement, suggesting that patients with lung adenocarcinomas should be tested for ROS1. Prospective clinical trials with crizotinib and other ROS1 inhibitors are ongoing or planned.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · cited 2×
“Our study mirrors the recently published phase I study that showed an overall response rate of 72%.(28) It is noteworthy that, in our study, the patients were pretreated with chemotherapy (except one patient who received first-line crizotinib) and were unselected for health status or comorbidities.”
BackgroundResultROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
New driver mutations in non-small-cell lung cancer
Pao, W., & Girard, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70087-5 · Cited by 1,128
New driver mutations in non-small-cell lung cancer
Tanoue, L. T. (2012) · Yearbook of Pulmonary Disease · doi:10.1016/j.ypdi.2012.01.036 · Cited by 831
Mazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668
Self-citationJänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Self-citationResponse to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
Drilon, A., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P., Ross, J., Miller, V., Ginsberg, M., Zakowski, M. F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0035 · Cited by 464
Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
Davies, K. D., Le, A. T., Theodoro, M. F., Skokan, M. C., Aisner, D. L., Berge, E. M., Terracciano, L. M., Cappuzzo, F., Incarbone, M., Roncalli, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0550 · Cited by 464
Self-citationAcquired Resistance to Crizotinib from a Mutation in CD74–ROS1
Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215530 · Cited by 416
Molecular Pathways: ROS1 Fusion Proteins in Cancer
Davies, K. D., & Doebele, R. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2851 · Cited by 373
CD74–NRG1 Fusions in Lung Adenocarcinoma
Fernandez-Cuesta, L., Plenker, D., Osada, H., Sun, R., Menon, R., Leenders, F., Ortiz-Cuaran, S., Peifer, M., Bos, M., Daßler, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0633 · Cited by 294
Self-citationCamidge, D. R., Ou, S.-H. I., Shapiro, G., Otterson, G. A., Villaruz, L. C., Villalona-Calero, M. A., Iafrate, A. J., Varella-Garcia, M., Dacic, S., Cardarella, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8001 · Cited by 256
Recent Clinical Advances in Lung Cancer Management
Johnson, D. H., Schiller, J. H., & Bunn, P. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1228 · Cited by 221
Expression and rearrangement of the ROS1 gene in human glioblastoma cells.
Birchmeier, C., Sharma, S., & Wigler, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9270 · Cited by 219
Pan, Y., Zhang, Y., Li, Y., Hu, H., Wang, L., Li, H., Wang, R., Ye, T., Luo, X., Zhang, Y., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.02.007 · Cited by 217
HER2 Mutation and Response to Trastuzumab Therapy in Non–Small-Cell Lung Cancer
Cappuzzo, F., Bemis, L., & Varella-Garcia, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmc060020 · Cited by 216
Self-citationCharest, A., Lane, K., McMahon, K., Park, J., Preisinger, E., Conroy, H., & Housman, D. (2003) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10207 · Cited by 211
Gandhi, L., Bahleda, R., Tolaney, S. M., Kwak, E. L., Cleary, J. M., Pandya, S. S., Hollebecque, A., Abbas, R., Ananthakrishnan, R., Berkenblit, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2787 · Cited by 198
Charest, A., Wilker, E. W., McLaughlin, M. E., Lane, K., Gowda, R., Coven, S., McMahon, K., Kovach, S., Feng, Y., Yaffe, M. B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1193 · Cited by 163
Yasuda, H., de Figueiredo-Pontes, L. L., Kobayashi, S., & Costa, D. B. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182570919 · Cited by 161
Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?
Antoniu, S. A. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.550880 · Cited by 159
A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib
Gautschi, O. P., Pauli, C., Strobel, K., Hirschmann, A., Printzen, G., Aebi, S. P., & Diebold, J. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182629903 · Cited by 141
Self-citationKim, H. R., Lim, S., Kim, H. J., Hwang, S., Park, J. K., Shin, E., Bae, M., Ou, S.-H. I., Wang, J., Jewell, S. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt220 · Cited by 128
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas
Mescam-Mancini, L., Lantuéjoul, S., Moro‐Sibilot, D., Rouquette, I., Souquet, P.-J., Audigier-Valette, C., Sabourin, J., Decroisette, C., Sakhri, L., Brambilla, E. M., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.019 · Cited by 122
Planchard, D., Mazières, J., Riely, G. J., Rudin, C. M., Barlési, F., Quoix, É., Souquet, P. J., Socinski, M. A., Switzky, J. C., Ma, B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8009 · Cited by 109
Self-citationWarth, A., Muley, T., Dienemann, H., Goeppert, B. F., Stenzinger, A., Schnabel, P. A., Schirmacher, P., Penzel, R., & Weichert, W. (2014) · Histopathology · doi:10.1111/his.12379 · Cited by 107
A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib
Gautschi, O. P., Zander, T., Aebersold, F., Strobel, K., Hirschmann, A., Aebi, S. P., & Diebold, J. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828a4d07 · Cited by 100
Self-citationCharacterization of ROS1 cDNA from a human glioblastoma cell line.
Birchmeier, C., O’Neill, K. E., Riggs, M. G., & Wigler, M. H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4799 · Cited by 99
Mok, T. S. K., Kim, D., Wu, Y.-L. L. C., Solomon, B., Nakagawa, K., Mekhail, T. M., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8002 · Cited by 84
Self-citationCha, Y. J., Lee, J. S., Kim, H. R., Lim, S. M., Cho, B. C., Lee, C. Y., & Shim, H. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103333 · Cited by 75
Kim, M. H., Shim, H. S., Kang, D. R., Jung, J. Y., Lee, C. Y., Kim, D. J., Lee, J. G., Bae, M. K., Kim, H. R., Lim, S. M., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.01.003 · Cited by 67
Go, H., Kim, D., Kim, D., Keam, B., Kim, T. M., Lee, S., Heo, D. S., Bang, Y., & Chung, D. H. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a4dd6e · Cited by 66
Mouse Model for ROS1-Rearranged Lung Cancer
Arai, Y., Totoki, Y., Takahashi, H., Nakamura, H. K., Hama, N., Kohno, T., Tsuta, K., Yoshida, A., Asamura, H., Mutoh, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056010 · Cited by 61
Bos, M. C. A., Gardizi, M., Schildhaus, H., Heukamp, L. C., Geist, T., Kaminsky, B., Zander, T., Nogová, L., Scheffler, M., Dietlein, M., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.018 · Cited by 46
Self-citationAcquired Resistance to Crizotinib from a Mutation in CD74–ROS1
Awad, M. M., Engelman, J. A., & Shaw, A. T. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1309091 · Cited by 44
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M. S., Neal, J. W., Adrouny, A., Cherry, A. M., & Wakelee, H. A. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.04.008 · Cited by 36
Miliary Brain Metastases in a Patient with ROS1-Rearranged Lung Adenocarcinoma: A Case Report
Dziadziuszko, K., Szurowska, E., Pienkowska, J. M., Jassem, J., & Dziadziuszko, R. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000091 · Cited by 18
Self-citation
Cited by
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
“1 months and ORR was 72% and 80%, respectively, although both of these studies enrolled only approximately 30 patients [217, 218].”
BackgroundSelf-citationNon–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,354
Self-citationNon–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J., Chirieac, L. R., D'Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,303
Metadata
- Authors
- Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A.-M. C., Léna, H., Monnet, I., Rothschild, S. I., Cappuzzo, F., Besse, B., Thiberville, L., Rouvière, D., Dziadziuszko, R., Smit, E. F., Wolf, J., Spirig, C., Pecuchet, N., Leenders, F., Heuckmann, J. M., Diebold, J., Milia, J. D., Thomas, R. K., & Gautschi, O.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-03-20
- Volume
- 33
- Issue
- 9
- Pages
- 992-999
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2119317963
- Cited by
- 369
- References
- 48
- FWCI
- 46.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.